{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:37:55Z","timestamp":1784565475552,"version":"3.55.0"},"reference-count":256,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.phrs.2019.104326","type":"journal-article","created":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T09:34:16Z","timestamp":1563701656000},"page":"104326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Beyond the boundaries of cardiology: Still untapped anticancer properties of the cardiovascular system-related drugs"],"prefix":"10.1016","volume":"147","author":[{"given":"Katarzyna","family":"Regulska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi\u0142osz","family":"Regulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Karolak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Michalak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Murias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Stanisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2019.104326_bib0005","series-title":"Key facts: What causes cancer?","author":"World Health Organization (WHO)","year":"2018"},{"key":"10.1016\/j.phrs.2019.104326_bib0010","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.drudis.2015.12.003","article-title":"COX-2 inhibitors: a novel strategy in the management of breast cancer","volume":"21","author":"Regulski","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2019.104326_bib0015","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.2174\/13816128113199990508","article-title":"The renin-angiotensin system as a target of novel anticancer therapy","volume":"19","author":"Regulska","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2019.104326_bib0020","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","article-title":"Molecular pathways: beta-adrenergic signaling in Cancer","volume":"18","author":"Cole","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.54987\/jobimb.v2i2.160","article-title":"Beyond anticoagulant: heparin as a potential anti-cancer agent","volume":"2","author":"Lokwani","year":"2014","journal-title":"J. Biochem. Microbiol. Biotechnol"},{"key":"10.1016\/j.phrs.2019.104326_bib0030","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.drudis.2019.03.010","article-title":"Can cardiovascular drugs support cancer treatment? The rationale for drug repurposing","volume":"24","author":"Regulska","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2019.104326_bib0035","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3390\/molecules22111932","article-title":"Anticancer and immunogenic properties of cardiac glycosides","volume":"22","author":"Schneider","year":"2017","journal-title":"Molecules."},{"key":"10.1016\/j.phrs.2019.104326_bib0040","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1016\/j.bbamem.2015.03.034","article-title":"Targeting ion channels for cancer therapy by repurposing the approved drugs","volume":"1848","author":"Kale","year":"2015","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.phrs.2019.104326_bib0045","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.2174\/1381612820666141112160013","article-title":"Chemistry and pharmacology of angiotensin-converting enzyme inhibitors","volume":"21","author":"Regulski","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2019.104326_bib0050","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/carcin\/bgn171","article-title":"The renin-angiotensin system and malignancy","volume":"29","author":"Ager","year":"2008","journal-title":"Carcinogenesis."},{"key":"10.1016\/j.phrs.2019.104326_bib0055","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.drudis.2014.06.026","article-title":"How to design a potent, specific, and stable angiotensin-converting enzyme inhibitor","volume":"19","author":"Regulska","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2019.104326_bib0060","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/1078-0432.CCR-04-1946","article-title":"Functional expression of the angiotensin II Type1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination","volume":"11","author":"Suganuma","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0065","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3892\/ijo_00000287","article-title":"Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1\/2, NF-kappaB and survivin","volume":"34","author":"Kinoshita","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0070","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin\u2013angiotensin system and cancer: old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib0075","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/14712598.6.3.243","article-title":"Manipulating the angiotensin system \u2013 new approaches to the treatment of solid tumours","volume":"6","author":"Ino","year":"2006","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.phrs.2019.104326_bib0080","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2407-10-134","article-title":"Changes in the renin angiotensin system during the development of colorectal cancer liver metastases","volume":"10","author":"Neo","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib0085","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1158\/1078-0432.CCR-04-1922","article-title":"The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion\/deletion polymorphism","volume":"11","author":"R\u00f6cken","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0090","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1042\/CS20120300","article-title":"Local bone marrow renin-angiotensin system in primitive, definitive and neoplastic haematopoiesis","volume":"124","author":"Haznedaroglu","year":"2013","journal-title":"Clin. Sci."},{"key":"10.1016\/j.phrs.2019.104326_bib0095","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1470320309352800","article-title":"Angiotensin-converting enzyme insertion\/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer","volume":"10","author":"Sierra D\u00edaz","year":"2009","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"10.1016\/j.phrs.2019.104326_bib0100","first-page":"1139","article-title":"Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor","volume":"2","author":"Uemura","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2019.104326_bib0105","first-page":"849","article-title":"Angiotensin II activates MAP kinase and NF-kappaB through angiotensin II type I receptor in human pancreatic cancer cells","volume":"25","author":"Amaya","year":"2004","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0110","doi-asserted-by":"crossref","first-page":"e35667","DOI":"10.1371\/journal.pone.0035667","article-title":"Angiotensin II facilitates breast Cancer cell migration and metastasis","volume":"7","author":"Rodrigues-Ferreira","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104326_bib0115","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6602961","article-title":"Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival","volume":"94","author":"Ino","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib0120","first-page":"5627","article-title":"Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer","volume":"36","author":"Arrieta","year":"2015","journal-title":"J. Immunother. Emphasis Tumor Immunol."},{"key":"10.1016\/j.phrs.2019.104326_bib0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11605-007-0403-9","article-title":"Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1\/2 signaling","volume":"12","author":"Anandanadesan","year":"2008","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.phrs.2019.104326_bib0130","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/carcin\/bgh236","article-title":"Inhibition of human lung cancer cell growth by angiotensin-(1-7)","volume":"25","author":"Gallagher","year":"2004","journal-title":"Carcinogenesis."},{"key":"10.1016\/j.phrs.2019.104326_bib0135","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ajpath.2011.11.027","article-title":"Regulation of monocyte chemoattractant Protein-1 through angiotensin II type 1 receptor in prostate Cancer","volume":"180","author":"Shirotake","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2019.104326_bib0140","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s11605-009-1055-8","article-title":"Angiotensin II regulates the expression of monocyte chemoattractant Protein-1 in pancreatic Cancer cells","volume":"13","author":"Chehl","year":"2009","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.phrs.2019.104326_bib0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy","volume":"9","author":"Pinter","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0150","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2174\/138161212799436593","article-title":"Role of renin-angiotensin system in inflammation, immunity and aging","volume":"18","author":"Capettini","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2019.104326_bib0155","first-page":"RA194","article-title":"Angiotensin II and vascular inflammation","volume":"11","author":"Cheng","year":"2005","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.phrs.2019.104326_bib0160","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI118698","article-title":"Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism","volume":"97","author":"Brink","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2019.104326_bib0165","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever","year":"1998","journal-title":"Lancet."},{"key":"10.1016\/j.phrs.2019.104326_bib0170","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2006.06.028","article-title":"ACE inhibitors may reduce esophageal Cancer incidence","volume":"131","author":"Lang","year":"2006","journal-title":"Gastroenterology."},{"key":"10.1016\/j.phrs.2019.104326_bib0175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jch.12228","article-title":"Lowered Cancer risk with ACE Inhibitors\/ARBs: a population-based cohort study","volume":"16","author":"Chiang","year":"2014","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.phrs.2019.104326_bib0180","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cllc.2016.07.008","article-title":"Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for advanced non-small-Cell lung Cancer","volume":"18","author":"Menter","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib0185","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000337979","article-title":"How Does Inhibition of the Renin-Angiotensin System Affect the Prognosis of Advanced Gastric Cancer Patients Receiving Platinum-Based Chemotherapy?","volume":"83","author":"Kim","year":"2012","journal-title":"Oncology."},{"key":"10.1016\/j.phrs.2019.104326_bib0190","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3892\/mco.2015.630","article-title":"Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients","volume":"3","author":"Osumi","year":"2015","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0195","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/bjc.2011.399","article-title":"Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer","volume":"105","author":"Tanaka","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib0200","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0205","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11060-017-2528-3","article-title":"Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and\/or bevacizumab","volume":"134","author":"Levin","year":"2017","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0210","doi-asserted-by":"crossref","first-page":"21359","DOI":"10.1038\/srep21359","article-title":"Impact of angiotensin I-converting enzyme inhibitors and angiotensin II Type-1 receptor blockers on survival of patients with NSCLC","volume":"6","author":"Miao","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2019.104326_bib0215","first-page":"1375","article-title":"The renin-angiotensin system blockers as adjunctive therapy for cancer: a meta-analysis of survival outcome","volume":"21","author":"Li","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2019.104326_bib0220","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13539-012-0072-8","article-title":"Evidence for an effect of ACE inhibitors on cancer cachexia","volume":"3","author":"Schanze","year":"2012","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.phrs.2019.104326_bib0225","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11060-018-2786-8","article-title":"Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?","volume":"138","author":"Happold","year":"2018","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0230","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12885-018-4292-y","article-title":"Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study","volume":"18","author":"Ho","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib0235","doi-asserted-by":"crossref","first-page":"k4209","DOI":"10.1136\/bmj.k4209","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study","volume":"363","author":"Hicks","year":"2018","journal-title":"BMJ."},{"key":"10.1016\/j.phrs.2019.104326_bib0240","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(01)05704-X","article-title":"Relation between drug treatment and cancer in hypertenslves in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial","volume":"358","author":"Lindholm","year":"2001","journal-title":"Lancet."},{"key":"10.1016\/j.phrs.2019.104326_bib0245","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.leukres.2008.09.029","article-title":"Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: a new role in the treatment of leukaemia for these agents","volume":"33","author":"De la Iglesia I\u00f1igo","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0250","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/02841860310022346","article-title":"Angiotensin converting enzyme inhibitors for cancer treatment?","volume":"43","author":"Lindberg","year":"2004","journal-title":"Acta Oncol. (Madr)."},{"key":"10.1016\/j.phrs.2019.104326_bib0255","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.4161\/cbt.6.8.4412","article-title":"Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread","volume":"6","author":"Carl-McGrath","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.phrs.2019.104326_bib0260","first-page":"2885","article-title":"Enalapril-induced apoptosis of acute promyelocytic leukaemia cells involves STAT5A","volume":"32","author":"Purclutepe","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0265","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1470320310379876","article-title":"Review: pathobiological aspects of the local bone marrow renin-angiotensin system: a review","volume":"11","author":"Haznedaroglu","year":"2010","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"10.1016\/j.phrs.2019.104326_bib0270","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1172\/JCI118838","article-title":"Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats","volume":"98","author":"Volpert","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2019.104326_bib0275","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejphar.2008.04.031","article-title":"Inhibitory profiles of captopril on matrix metalloproteinase-9 activity","volume":"588","author":"Yamamoto","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104326_bib0280","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.ejso.2005.04.003","article-title":"Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models","volume":"31","author":"Williams","year":"2005","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0285","doi-asserted-by":"crossref","first-page":"H3057","DOI":"10.1152\/ajpheart.00447.2006","article-title":"Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure","volume":"292","author":"Brower","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2019.104326_bib0290","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/FJC.0000000000000077","article-title":"Imidapril and enalapril similarly inhibit plasma matrix metalloproteinase activities and attenuate left ventricular remodeling in patients with acute myocardial infarction","volume":"63","author":"Yokota","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104326_bib0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165371","article-title":"Angiotensin converting enzyme regulates cell proliferation and migration","volume":"11","author":"de Alvarenga","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104326_bib0300","first-page":"441","article-title":"Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities","volume":"17","author":"Yanase","year":"2007","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2019.104326_bib0305","first-page":"6038","article-title":"Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis","volume":"9","author":"Noguchi","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0310","first-page":"155","article-title":"Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities","volume":"15","author":"Yoshiji","year":"2006","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2019.104326_bib0315","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ijc.20400","article-title":"Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model","volume":"112","author":"de Groot-Besseling","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib0320","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.immuni.2012.10.015","article-title":"Angiotensin II drives the production of tumor-promoting macrophages","volume":"38","author":"Cortez-Retamozo","year":"2013","journal-title":"Immunity."},{"key":"10.1016\/j.phrs.2019.104326_bib0325","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/ijc.28128","article-title":"Inhibition of the renin-angiotensin system improves physiological outcomes in mice with mild or severe cancer cachexia","volume":"133","author":"Murphy","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib0330","first-page":"4176","article-title":"Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis","volume":"62","author":"Miyajima","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0335","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0006-291X(02)00496-5","article-title":"Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis","volume":"294","author":"Fujita","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2019.104326_bib0340","first-page":"355","article-title":"Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities","volume":"22","author":"Noguchi","year":"2009","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2019.104326_bib0345","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3892\/ijo.2017.4177","article-title":"Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest","volume":"51","author":"Samukawa","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0350","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1172\/JCI16645","article-title":"Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth","volume":"112","author":"Egami","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2019.104326_bib0355","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1073\/pnas.1818357116","article-title":"Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma","volume":"116","author":"Zhao","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2019.104326_bib0360","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.phrs.2019.104326_bib0365","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.phrs.2019.104326_bib0370","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events","volume":"358","author":"ONTARGET Investigators","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0375","doi-asserted-by":"crossref","unstructured":"Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, S. Yusuf, K. Teo, C. Anderson, J. Pogue, L. Dyal, I. Copland, H. Schumacher, G. Dagenais, P. Sleight, Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial., Lancet (London, England). 372 (2008) 1174\u201383. doi:10.1016\/S0140-6736(08)61242-8.","DOI":"10.1016\/S0140-6736(08)61242-8"},{"key":"10.1016\/j.phrs.2019.104326_bib0380","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"Yusuf","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0385","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0390","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.HYP.0000236119.96301.f2","article-title":"The valsartan antihypertensive long-term use evaluation (VALUE) trial: outcomes in patients receiving monotherapy","volume":"48","author":"Julius","year":"2006","journal-title":"Hypertension."},{"key":"10.1016\/j.phrs.2019.104326_bib0395","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/HJH.0b013e3282f3ef5e","article-title":"Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials","volume":"26","author":"Coleman","year":"2008","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2019.104326_bib0400","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0405","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals","volume":"29","author":"ARB Trialists Collaboration","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2019.104326_bib0410","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.110.007336","article-title":"Use of angiotensin receptor blockers and the risk of cancer","volume":"123","author":"Pasternak","year":"2011","journal-title":"Circulation."},{"key":"10.1016\/j.phrs.2019.104326_bib0415","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e2697","article-title":"Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database","volume":"344","author":"Bhaskaran","year":"2012","journal-title":"BMJ."},{"key":"10.1016\/j.phrs.2019.104326_bib0420","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/1470320315607391","article-title":"Angiotensin receptor blockers use and the risk of lung cancer: a meta-analysis","volume":"16","author":"Zhang","year":"2015","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"10.1016\/j.phrs.2019.104326_bib0425","series-title":"The U.S. Food and Drug Administration (FDA), FDA Drug Safety Communication : No Increase in Risk of Cancer With Certain Blood Pressure Drugs--Angiotensin Facts About Angiotensin Receptor Blockers","year":"2011"},{"key":"10.1016\/j.phrs.2019.104326_bib0430","article-title":"TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): preliminary feasibility and R0 resection rates from a prospective phase II study","volume":"35","author":"Murphy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0435","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lfs.2016.04.029","article-title":"Evaluation of role of telmisartan in combination with 5-fluorouracil in gastric cancer cachexia","volume":"154","author":"Sukumaran","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2019.104326_bib0440","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10147-005-0520-y","article-title":"Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer","volume":"10","author":"Uemura","year":"2005","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0445","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2217\/pgs.15.152","article-title":"The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference","volume":"17","author":"He","year":"2016","journal-title":"Pharmacogenomics."},{"key":"10.1016\/j.phrs.2019.104326_bib0450","doi-asserted-by":"crossref","first-page":"9567","DOI":"10.7314\/APJCP.2014.15.22.9567","article-title":"Are Beta Blockers New Potential Anticancer Agents?","volume":"15","author":"Akbar","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.phrs.2019.104326_bib0455","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/carcin\/bgr251","article-title":"Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention","volume":"33","author":"Schuller","year":"2012","journal-title":"Carcinogenesis."},{"key":"10.1016\/j.phrs.2019.104326_bib0460","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.semcancer.2013.08.009","article-title":"\u03b2-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy","volume":"23","author":"Tang","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.phrs.2019.104326_bib0465","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1373\/49.4.586","article-title":"Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas","volume":"49","author":"Meijer","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2019.104326_bib0470","series-title":"Neuronal Act. Tumor Tissue, KARGER, Basel","first-page":"91","article-title":"Neoneurogenesis and the neuro-neoplastic synapse","author":"Palm","year":"2007"},{"key":"10.1016\/j.phrs.2019.104326_bib0475","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.bbi.2012.01.013","article-title":"Chronic stress enhances progression of acute lymphoblastic leukemia via \u03b2-adrenergic signaling","volume":"26","author":"Lamkin","year":"2012","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.phrs.2019.104326_bib0480","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4161\/cbt.10.1.12260","article-title":"Role for catecholamines in tumor progression","volume":"10","author":"Yang","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.phrs.2019.104326_bib0485","first-page":"3504","article-title":"Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease","volume":"55","author":"Park","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0490","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00432-015-2078-z","article-title":"The role of stress and beta-adrenergic system in melanoma: current knowledge and possible therapeutic options","volume":"142","author":"Colucci","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0495","first-page":"584","article-title":"Beta-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice","volume":"59","author":"Lin","year":"2012","journal-title":"Hepatogastroenterology."},{"key":"10.1016\/j.phrs.2019.104326_bib0500","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jcp.25092","article-title":"Selective \u03b22-AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR-Akt\/ERK1\/2 Signaling, G1-Phase Arrest, and Apoptosis","volume":"231","author":"Chin","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.phrs.2019.104326_bib0505","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1172\/JCI40802","article-title":"Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis","volume":"120","author":"Sood","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2019.104326_bib0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2011.04.055","article-title":"\u03b22-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction","volume":"665","author":"Shan","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104326_bib0515","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/onc.2015.58","article-title":"\u03b22-AR signaling controls trastuzumab resistance-dependent pathway","volume":"35","author":"Liu","year":"2016","journal-title":"Oncogene."},{"key":"10.1016\/j.phrs.2019.104326_bib0520","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10585-004-4226-8","article-title":"SGK1, a potential regulator of c-fms related breast cancer aggressiveness","volume":"21","author":"Tangir","year":"2004","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.phrs.2019.104326_bib0525","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001363","article-title":"Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast Cancer bone metastasis in mice","volume":"10","author":"Campbell","year":"2012","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2019.104326_bib0530","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/CMAR.S39153","article-title":"The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms","volume":"4","author":"Luong","year":"2012","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0535","doi-asserted-by":"crossref","first-page":"628","DOI":"10.18632\/oncotarget.197","article-title":"Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival","volume":"1","author":"Powe","year":"2010","journal-title":"Oncotarget."},{"key":"10.1016\/j.phrs.2019.104326_bib0540","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm1447","article-title":"Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma","volume":"12","author":"Thaker","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0545","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/SLA.0b013e318211d7b5","article-title":"Improving postoperative immune status and resistance to Cancer metastasis","volume":"253","author":"Goldfarb","year":"2011","journal-title":"Ann. Surg."},{"key":"10.1016\/j.phrs.2019.104326_bib0550","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12967-016-1031-5","article-title":"Repurposing of approved cardiovascular drugs","volume":"14","author":"Ishida","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0555","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","article-title":"Beta blockers and breast Cancer mortality: a population- based study","volume":"29","author":"Barron","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0560","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1200\/JCO.2010.33.4441","article-title":"Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast Cancer","volume":"29","author":"Melhem-Bertrandt","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0565","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10654-007-9135-0","article-title":"Medication use and the risk of breast cancer","volume":"22","author":"Davis","year":"2007","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.phrs.2019.104326_bib0570","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/sj.jhh.1002075","article-title":"Hypertension, diuretics and breast cancer risk","volume":"20","author":"Largent","year":"2006","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.phrs.2019.104326_bib0575","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archinternmed.2011.131","article-title":"Treatment with \u03b2-blockers and reduced disease progression in patients with thick melanoma","volume":"171","author":"De Giorgi","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0580","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1055-9965.EPI-11-0249","article-title":"\u0392-blockers and survival among danish patients with malignant melanoma: a population-based cohort study","volume":"20","author":"Lemeshow","year":"2011","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.phrs.2019.104326_bib0585","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2125.2011.03980.x","article-title":"Does \u03b2-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study","volume":"72","author":"Shah","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104326_bib0590","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1038\/s41598-017-02913-8","article-title":"Pre- and post-diagnostic \u03b2-blocker use and lung cancer survival: a population-based cohort study","volume":"7","author":"Weberpals","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2019.104326_bib0595","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mds616","article-title":"Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy","volume":"24","author":"Wang","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0600","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/sj.bjc.6602490","article-title":"A cohort study of antihypertensive treatments and risk of renal cell cancer","volume":"92","author":"Fryzek","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib0605","first-page":"535","article-title":"Antihypertensive drug use and the risk of prostate Cancer (Canada)","volume":"15","author":"Perron","year":"2004","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.phrs.2019.104326_bib0610","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2012.07.102","article-title":"Impact of beta blockers on epithelial ovarian cancer survival","volume":"127","author":"Diaz","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0615","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2174\/157018006778341192","article-title":"Is beta-blocker treatment associated with a decrease in the risk of Cancer","volume":"3","author":"Algazi","year":"2006","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.phrs.2019.104326_bib0620","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2015.02.015","article-title":"Carvedilol use is associated with reduced cancer risk: a nationwide population-based cohort study","volume":"184","author":"Lin","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2019.104326_bib0625","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00432-014-1658-7","article-title":"Meta-analysis of the effects of beta blocker on survival time in cancer patients","volume":"140","author":"Choi","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0630","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/CEJ.0000000000000192","article-title":"\u03b2-Blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies","volume":"25","author":"Zhong","year":"2016","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.phrs.2019.104326_bib0635","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.2147\/OTT.S167422","article-title":"The effects of beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patients","volume":"11","author":"Na","year":"2018","journal-title":"Onco. Targets. Ther. Volume"},{"key":"10.1016\/j.phrs.2019.104326_bib0640","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bja.2018.03.024","article-title":"Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies","volume":"121","author":"Yap","year":"2018","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.phrs.2019.104326_bib0645","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1158\/0008-5472.CAN-10-0522","article-title":"The sympathetic nervous system induces a metastatic switch in primary breast Cancer","volume":"70","author":"Sloan","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0650","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1158\/1541-7786.MCR-11-0130","article-title":"Norepinephrine promotes the 1-Integrin-Mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GRO release","volume":"10","author":"Strell","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0655","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1158\/1078-0432.CCR-08-2966","article-title":"Surgical stress promotes tumor growth in ovarian carcinoma","volume":"15","author":"Lee","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0660","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1078-0432.CCR-05-1698","article-title":"Stress hormone-mediated invasion of ovarian Cancer cells","volume":"12","author":"Sood","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0665","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/ncomms2413","article-title":"Src activation by \u03b2-adrenoreceptors is a key switch for tumour metastasis","volume":"4","author":"Armaiz-Pena","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2019.104326_bib0670","doi-asserted-by":"crossref","first-page":"35462","DOI":"10.1074\/jbc.M110.109579","article-title":"Stress effects on FosB- and Interleukin-8 (IL8)-driven ovarian Cancer growth and metastasis","volume":"285","author":"Shahzad","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.104326_bib0675","doi-asserted-by":"crossref","first-page":"10389","DOI":"10.1158\/0008-5472.CAN-07-0858","article-title":"Neuroendocrine modulation of signal transducer and activator of Transcription-3 in ovarian Cancer","volume":"67","author":"Landen","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0680","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.4049\/jimmunol.0903301","article-title":"Improving Survival Rates in Two Models of Spontaneous Postoperative Metastasis in Mice by Combined Administration of a \u03b2-Adrenergic Antagonist and a Cyclooxygenase-2 Inhibitor","volume":"184","author":"Glasner","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2019.104326_bib0685","first-page":"4510","article-title":"The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid","volume":"59","author":"Schuller","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0690","doi-asserted-by":"crossref","first-page":"10357","DOI":"10.1158\/0008-5472.CAN-06-2496","article-title":"Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0695","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060021","article-title":"Targeting of Beta Adrenergic receptors results in therapeutic efficacy against models of Hemangioendothelioma and angiosarcoma","volume":"8","author":"Stiles","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104326_bib0700","doi-asserted-by":"crossref","first-page":"14094","DOI":"10.1074\/jbc.M611370200","article-title":"Epinephrine protects Cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation","volume":"282","author":"Sastry","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.104326_bib0705","first-page":"874","article-title":"Behavioral stress accelerates prostate cancer development in mice","volume":"123","author":"Hassan","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2019.104326_bib0710","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ijc.20410","article-title":"Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs","volume":"112","author":"Lang","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib0715","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/ijc.21723","article-title":"The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB\/c nude mice is inhibited by \u03b2-blockers","volume":"118","author":"Palm","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib0720","first-page":"825","article-title":"Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol","volume":"22","author":"Guo","year":"2009","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2019.104326_bib0725","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4161\/cbt.10.1.11944","article-title":"\u03b22 -adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NF-\u03baB and AP-1","volume":"10","author":"Zhang","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.phrs.2019.104326_bib0730","first-page":"2866","article-title":"Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers","volume":"61","author":"Masur","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0735","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.lfs.2011.04.007","article-title":"Effects of adrenaline in human colon adenocarcinoma HT-29 cells","volume":"88","author":"Wong","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2019.104326_bib0740","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.taap.2008.08.012","article-title":"Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: involvement of nicotinic acetylcholine receptor (nAChR) and \u03b2-adrenergic receptor signaling pathways","volume":"233","author":"Shin","year":"2008","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104326_bib0745","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/toxsci\/kfl118","article-title":"Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells","volume":"96","author":"Shin","year":"2007","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.phrs.2019.104326_bib0750","first-page":"1669","article-title":"The \u03b2-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor \u03baB signaling","volume":"24","author":"Liao","year":"2010","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2019.104326_bib0755","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbi.2008.10.005","article-title":"Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression","volume":"23","author":"Yang","year":"2009","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.phrs.2019.104326_bib0760","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.18632\/oncotarget.2652","article-title":"Norepinephrine promotes tumor microenvironment reactivity through \u03b23-adrenoreceptors during melanoma progression","volume":"6","author":"Calvani","year":"2015","journal-title":"Oncotarget."},{"key":"10.1016\/j.phrs.2019.104326_bib0765","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/labinvest.2012.175","article-title":"\u03b2-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines","volume":"93","author":"Moretti","year":"2013","journal-title":"Lab. Investig."},{"key":"10.1016\/j.phrs.2019.104326_bib0770","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1747-1028-8-1","article-title":"The role of \u03b2-adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cells","volume":"8","author":"Ji","year":"2013","journal-title":"Cell Div."},{"key":"10.1016\/j.phrs.2019.104326_bib0775","first-page":"387","article-title":"Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril","volume":"24","author":"Stanojkovic","year":"2005","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0780","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1038\/bjc.2013.205","article-title":"\u03b2-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma","volume":"108","author":"Pasquier","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib0785","first-page":"74","article-title":"Triple effect of doxorubicin, 5-Fluorouracil, propranolol on cell survival on MCF-7 breast Cancer cell line","volume":"07","author":"Eroglu","year":"2019","journal-title":"J. Biosci. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0790","doi-asserted-by":"crossref","first-page":"797","DOI":"10.18632\/oncotarget.343","article-title":"Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment","volume":"2","author":"Pasquier","year":"2011","journal-title":"Oncotarget."},{"key":"10.1016\/j.phrs.2019.104326_bib0795","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0800","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.11-3-306","article-title":"The role of statins in cancer therapy","volume":"11","author":"Hindler","year":"2006","journal-title":"Oncologist."},{"key":"10.1016\/j.phrs.2019.104326_bib0805","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.phrs.2019.104326_bib0810","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.1996.03530250059028","article-title":"Carcinogenicity of lipid-lowering drugs","volume":"275","author":"Newman","year":"1996","journal-title":"JAMA."},{"key":"10.1016\/j.phrs.2019.104326_bib0815","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00001648-200205000-00005","article-title":"Statin use and the risk of breast and prostate cancer","volume":"13","author":"Coogan","year":"2002","journal-title":"Epidemiology"},{"key":"10.1016\/j.phrs.2019.104326_bib0820","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0825","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0830","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1445-5994.1994.tb04447.x","article-title":"Cholesterol reduction and death from noncoronary causes: evidence from randomised controlled trials*","volume":"24","author":"MacMahonf","year":"1994","journal-title":"Aust. N. Z. J. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0835","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","volume":"288","year":"2002","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"10.1016\/j.phrs.2019.104326_bib0840","doi-asserted-by":"crossref","first-page":"41","DOI":"10.13105\/wjma.v5.i2.41","article-title":"Statin use and risk of cancer: an overview of meta-analyses","volume":"5","author":"Undela","year":"2017","journal-title":"World J. Meta-Analysis."},{"key":"10.1016\/j.phrs.2019.104326_bib0845","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1053-0770(99)90192-1","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels","volume":"13","author":"Downs","year":"1999","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"10.1016\/j.phrs.2019.104326_bib0850","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","article-title":"Statins and the risk of colorectal Cancer","volume":"352","author":"Poynter","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0855","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1089\/154099903322447710","article-title":"Lipid-lowering drug use and breast Cancer in older women : a prospective study","volume":"12","author":"Cauley","year":"2003","journal-title":"J. Womens Heal."},{"key":"10.1016\/j.phrs.2019.104326_bib0860","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1001\/archinte.160.15.2363","article-title":"3-hydroxy-3-Methylglutaryl coenzyme a reductase inhibitors and the risk of Cancer","volume":"160","author":"Blais","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0865","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/aje\/kwi203","article-title":"Statins and Prostate Cancer Risk: A Case-Control Study","volume":"162","author":"Shannon","year":"2005","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.phrs.2019.104326_bib0870","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1200\/JCO.2004.02.027","article-title":"The risk of Cancer in users of statins","volume":"22","author":"Graaf","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0875","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jnci\/djr291","article-title":"Statin prescriptions and breast Cancer recurrence risk: a danish nationwide prospective cohort study","volume":"103","author":"Ahern","year":"2011","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.phrs.2019.104326_bib0880","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/ijc.30185","article-title":"Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis","volume":"139","author":"Manthravadi","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib0885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-017-4246-0","article-title":"The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis","volume":"164","author":"Liu","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2019.104326_bib0890","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ctrv.2015.04.005","article-title":"Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies","volume":"41","author":"Zhong","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2019.104326_bib0895","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00000421-199812000-00010","article-title":"A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme","volume":"21","author":"Larner","year":"1998","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0900","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0188-0128(98)00018-9","article-title":"Security and maximal tolerated doses of fluvastatin in pediatric Cancer patients","volume":"30","author":"L\u00f3pez-Aguilar","year":"1999","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0905","first-page":"886","article-title":"Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma","volume":"84","author":"Kawata","year":"2001","journal-title":"A randomized controlled trial, Br. J. Cancer."},{"key":"10.1016\/j.phrs.2019.104326_bib0910","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000156702","article-title":"Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma","volume":"78","author":"Graf","year":"2008","journal-title":"Digestion."},{"key":"10.1016\/j.phrs.2019.104326_bib0915","first-page":"1099","article-title":"Treatment of HCC with pravastatin, octreotide, or gemcitabine--a critical evaluation","volume":"51","author":"Lersch","year":"2004","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.phrs.2019.104326_bib0920","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/bjh.13035","article-title":"SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia","volume":"167","author":"Advani","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.phrs.2019.104326_bib0925","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/joim.12806","article-title":"Statins: a role in breast cancer therapy?","volume":"284","author":"Borgquist","year":"2018","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0930","first-page":"5363","article-title":"Clinical potential of statins in prostate Cancer radiation therapy","volume":"37","author":"Hutchinson","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0935","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2016.69.7391","article-title":"Placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung Cancer (LUNGSTAR)","volume":"35","author":"Seckl","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib0940","first-page":"2223","article-title":"Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells","volume":"5","author":"Agarwal","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0945","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0959-8049(97)10034-X","article-title":"Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice","volume":"34","author":"Feleszko","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib0950","first-page":"141","article-title":"Synergistic interaction of lovastatin and paclitaxel in human cancer cells","volume":"1","author":"Holstein","year":"2001","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2019.104326_bib0955","first-page":"2044","article-title":"Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice","volume":"6","author":"Feleszko","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0960","first-page":"69","article-title":"Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice","volume":"42","author":"Feleszko","year":"1995","journal-title":"Neoplasma"},{"key":"10.1016\/j.phrs.2019.104326_bib0965","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40364-018-0140-0","article-title":"Combination statin and chemotherapy inhibits proliferation and cytotoxicity of an aggressive natural killer cell leukemia","volume":"6","author":"Henslee","year":"2018","journal-title":"Biomark. Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0970","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/jphp.12707","article-title":"Statins anticancer targeted delivery systems: re-purposing an old molecule","volume":"69","author":"Safwat","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104326_bib0975","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jddst.2016.01.004","article-title":"Pravastatin-loaded chitosan nanoparticles: formulation, characterization and cytotoxicity studies","volume":"32","author":"Badran","year":"2016","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.phrs.2019.104326_bib0980","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nm0396-326","article-title":"HMG\u2013CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P\u2013glycoprotein\u2013expressing cells","volume":"2","author":"Dimitroulakos","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib0985","first-page":"2067","article-title":"Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin","volume":"7","author":"Wong","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib0990","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/carcin\/22.8.1139","article-title":"Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study","volume":"22","author":"Denoyelle","year":"2001","journal-title":"Carcinogenesis."},{"key":"10.1016\/j.phrs.2019.104326_bib0995","doi-asserted-by":"crossref","first-page":"8648","DOI":"10.1158\/1078-0432.CCR-04-1568","article-title":"3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis","volume":"10","author":"Horiguchi","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib1000","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/0016-5085(92)90032-T","article-title":"Inhibition of pancreatic adenocarcinoma cell growth by lovastatin","volume":"103","author":"Sumi","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2019.104326_bib1005","first-page":"2761","article-title":"Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells","volume":"20","author":"Bouterfa","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib1010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3109\/10428199709055590","article-title":"A comparison of the effect of the 3-Hydroxy-3-Methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors","volume":"24","author":"Newman","year":"1997","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.phrs.2019.104326_bib1015","first-page":"941","article-title":"Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells","volume":"2","author":"Collisson","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2019.104326_bib1020","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1023\/A:1020355621043","article-title":"Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells","volume":"19","author":"Farina","year":"2002","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.phrs.2019.104326_bib1025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1096\/fj.03-0261fje","article-title":"Lovastatin inhibits Rho-regulated expression of E-selectin by TNF\u03b1 and attenuates tumor cell adhesion","volume":"18","author":"N\u00fcbel","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2019.104326_bib1030","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/gast.2002.31093","article-title":"3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis","volume":"122","author":"Kusama","year":"2002","journal-title":"Gastroenterology."},{"key":"10.1016\/j.phrs.2019.104326_bib1035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0021-9150(03)00299-5","article-title":"Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells","volume":"170","author":"Frick","year":"2003","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.phrs.2019.104326_bib1040","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/hc0602.103393","article-title":"Statins have biphasic effects on angiogenesis","volume":"105","author":"Weis","year":"2002","journal-title":"Circulation."},{"key":"10.1016\/j.phrs.2019.104326_bib1045","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.RES.0000014081.30867.F8","article-title":"Double-edged role of statins in angiogenesis signaling","volume":"90","author":"Urbich","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2019.104326_bib1050","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/01.RES.0000028149.15986.4C","article-title":"3-hydroxy-3-Methylglutaryl coenzyme a reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA","volume":"91","author":"Park","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2019.104326_bib1055","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1160\/TH08-01-0032","article-title":"Heparin and low-molecular-weight heparin","volume":"99","author":"Gray","year":"2008","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.phrs.2019.104326_bib1060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3909\/ricm0778","article-title":"Heparin: physiology, pharmacology, and clinical application","volume":"16","author":"Lee","year":"2015","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib1065","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1160\/TH08-12-0832","article-title":"Anti-cancer properties of low-molecular-weight heparin: preclinical evidence","volume":"102","author":"Mousa","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.phrs.2019.104326_bib1070","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1245\/s10434-006-9183-9","article-title":"A systematic review of deep venous thrombosis prophylaxis in Cancer patients: implications for improving quality","volume":"14","author":"Leonardi","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib1075","first-page":"3","article-title":"Anti-metastatic activities of heparins","volume":"5","author":"Simka","year":"2009","journal-title":"Int. J. Cancer Res. Mol. Mech."},{"key":"10.1016\/j.phrs.2019.104326_bib1080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5114\/pr.2015.54034","article-title":"Administration of low molecular weight heparins for prolonging the survival of patients with cancer","volume":"2","author":"Majewski","year":"2015","journal-title":"Phlebol. Rev."},{"key":"10.1016\/j.phrs.2019.104326_bib1085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0049-3848(07)70143-3","article-title":"Cancer, thrombosis and heparin-induced thrombocytopenia","volume":"120","author":"Prandoni","year":"2007","journal-title":"Thromb. Res."},{"key":"10.1016\/j.phrs.2019.104326_bib1090","series-title":"Madame Curie Biosci. Database, Landes Bioscience, Austin (TX)","article-title":"Regulation of tissue factor expression","author":"Ruf","year":"2000"},{"key":"10.1016\/j.phrs.2019.104326_bib1095","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.critrevonc.2006.07.007","article-title":"Mechanisms of heparin induced anti-cancer activity in experimental cancer models","volume":"61","author":"Niers","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2019.104326_bib1100","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/CIRCULATIONAHA.105.567297","article-title":"Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications","volume":"113","author":"Steffel","year":"2006","journal-title":"Circulation."},{"key":"10.1016\/j.phrs.2019.104326_bib1105","first-page":"963","article-title":"Effects of serine protease inhibitor FOY-305 and heparin on the growth of squamous cell carcinoma","volume":"13","author":"Ohkoshi","year":"1993","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib1110","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00384-003-0535-7","article-title":"Effect of low molecular weight heparin on intra-abdominal metastasis in a laparoscopic experimental study","volume":"19","author":"Pross","year":"2004","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.phrs.2019.104326_bib1115","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1046\/j.1538-7836.2003.00341.x","article-title":"Antimetastatic effect of tinzaparin, a low-molecular-weight heparin","volume":"1","author":"Amirkhosravi","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.phrs.2019.104326_bib1120","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-05-1131","article-title":"Differential metastasis inhibition by clinically relevant levels of heparins--Correlation with selectin inhibition, not antithrombotic activity","volume":"11","author":"Stevenson","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib1125","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/sj.bjc.6600307","article-title":"Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung","volume":"86","author":"Ono","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib1130","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1200\/JCO.2004.10.002","article-title":"Low molecular weight heparin, therapy with Dalteparin, and survival in advanced Cancer: the fragmin advanced malignancy outcome study (FAMOUS)","volume":"22","author":"Kakkar","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib1135","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1200\/JCO.2005.03.134","article-title":"The effect of low molecular weight heparin on survival in patients with advanced malignancy","volume":"23","author":"Klerk","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib1140","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1200\/JCO.2005.03.133","article-title":"Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with Cancer and venous thromboembolism","volume":"23","author":"Lee","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib1145","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-Weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with Cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib1150","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib1155","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s00432-016-2131-6","article-title":"Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms","volume":"142","author":"Zhang","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib1160","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1538-7836.2004.00871.x","article-title":"A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer","volume":"2","author":"Altinbas","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.phrs.2019.104326_bib1165","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.thromres.2013.09.026","article-title":"Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study","volume":"132","author":"Lecumberri","year":"2013","journal-title":"Thromb. Res."},{"key":"10.1016\/j.phrs.2019.104326_bib1170","series-title":"Cochrane Database Syst. Rev","article-title":"Parenteral anticoagulation in ambulatory patients with cancer","author":"Akl","year":"2014"},{"key":"10.1016\/j.phrs.2019.104326_bib1175","doi-asserted-by":"crossref","first-page":"800","DOI":"10.7326\/0003-4819-130-10-199905180-00003","article-title":"Low-molecular-Weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis","volume":"130","author":"Gould","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib1180","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/0140-6736(92)92064-M","article-title":"Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin","volume":"339","author":"Green","year":"1992","journal-title":"Lancet."},{"key":"10.1016\/j.phrs.2019.104326_bib1185","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0889-8588(05)70176-3","article-title":"Antithrombotic therapy in GYNECOLOGIC surgery and GYNECOLOGIC ONCOLOGY","volume":"14","author":"von Tempelhoff","year":"2000","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.phrs.2019.104326_bib1190","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJM199204093261502","article-title":"Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis","volume":"326","author":"Hull","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib1195","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000081508","article-title":"Low-molecular-Weight heparin and Cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months","volume":"33","author":"Conti","year":"2003","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"10.1016\/j.phrs.2019.104326_bib1200","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/jth.12595","article-title":"The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials","volume":"12","author":"Sanford","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.phrs.2019.104326_bib1205","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mdx716","article-title":"Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial","volume":"29","author":"Ek","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2019.104326_bib1210","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.rmr.2011.03.015","article-title":"Effet de la tinzaparine sur la mortalit\u00e9 du cancer bronchique non \u00e0 petites cellules op\u00e9r\u00e9","volume":"28","author":"Meyer","year":"2011","journal-title":"Rev. Mal. Respir."},{"key":"10.1016\/j.phrs.2019.104326_bib1215","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/1471-2407-8-361","article-title":"Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)","volume":"8","author":"Riess","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib1220","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood.V96.10.3302","article-title":"Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells","volume":"96","author":"Palumbo","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2019.104326_bib1225","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/cncr.26518","article-title":"Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: procoagulant nature of osteosarcoma","volume":"118","author":"Ichikawa","year":"2012","journal-title":"Cancer."},{"key":"10.1016\/j.phrs.2019.104326_bib1230","first-page":"49","article-title":"Are low molecular weight heparins the same?","volume":"93","author":"Mousa","year":"2004","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.phrs.2019.104326_bib1235","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1160\/TH06-05-0289","article-title":"Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin","volume":"96","author":"Mousa","year":"2006","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.phrs.2019.104326_bib1240","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1021\/bi00366a050","article-title":"Chemically modified heparins as inhibitors of heparan sulfate specific endo-.beta.-Glucuronidase (heparanase) of metastatic melanoma cells","volume":"25","author":"Irimura","year":"1986","journal-title":"Biochemistry."},{"key":"10.1016\/j.phrs.2019.104326_bib1245","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1096\/fj.07-8450com","article-title":"P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins","volume":"21","author":"Hostettler","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2019.104326_bib1250","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc1388","article-title":"Cancer and the chemokine network","volume":"4","author":"Balkwill","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2019.104326_bib1255","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10585-007-9133-3","article-title":"Inhibition of the CXCR4\/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases","volume":"25","author":"Kim","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.phrs.2019.104326_bib1260","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2174\/138955706778195180","article-title":"Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities","volume":"6","author":"Ludwig","year":"2006","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104326_bib1265","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.bjp.0706344","article-title":"A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity","volume":"146","author":"Takahashi","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104326_bib1270","first-page":"6196","article-title":"Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro","volume":"60","author":"Collen","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2019.104326_bib1275","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/jop.1994.10.273","article-title":"Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization","volume":"10","author":"Lepri","year":"1994","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2019.104326_bib1280","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/HYPERTENSIONAHA.111.189258","article-title":"Blood Pressure and Risk of Cancer Incidence and Mortality in the Metabolic Syndrome and Cancer Project","volume":"59","author":"Stocks","year":"2012","journal-title":"Hypertension"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819303524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819303524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:04:24Z","timestamp":1760911464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819303524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":256,"alternative-id":["S1043661819303524"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104326","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond the boundaries of cardiology: Still untapped anticancer properties of the cardiovascular system-related drugs","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104326"}}